




Meningococcal Vaccine Timing

MenACWY (MCV4) and MenB vaccines each protect against different serogroups. They may be given at the same visit.

For high-risk populations (increased exposure to meningococcal disease, HIV infection, complement deficiencies or, asplenia), see recommendations at EZIZ.org/assets/docs/IMM-1218.pdf

Routine	As needed to provide short-term protection against most strains of serogroup B meningococcal disease
<p>All 11-12 years^{1,2}</p> 	<p>16-23 years (Preferred age is 16–18 years)</p> <p>1st dose MenB Bexsero®</p> <p>1 month →</p> <p>2nd dose MenB Bexsero®</p> <p>OR</p> <p>1st dose MenB Trumenba®</p> <p>1–2 months⁴ →</p> <p>2nd dose⁴ MenB⁴ Trumenba®</p> <p>6 months between 1st and last dose →</p> <p>3rd dose MenB Trumenba®</p> <p>Use the same brand of MenB vaccine for each dose in the series.</p>
<p>All 16 years^{2,3}</p> <p>Booster dose</p> 	
<p>Catch-up for first-year college students 19–21 years of age if</p> <ul style="list-style-type: none"> • No prior vaccination OR • Received 1st dose when younger than 16 years 	

Notes:

1. HIV-infected persons are recommended to receive 2 MenACWY (MCV4) doses, 2 months apart as the primary series if not yet immunized before age 11-12 years.
2. MenACWY (MCV4) vaccines protect against serogroups A, C, W-135, and Y.
3. If the first dose of MenACWY (MCV4) is given at age 16 years, no booster dose is needed.
4. Also licensed for optional two-dose schedule given at 0 and 6 months. The choice of dosing schedule may depend on the risk of exposure and the patient's susceptibility to serogroup B disease.

For further details, see: www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html.



California Department of Public Health,
Immunization Branch
This publication was supported by Grant
Number H23/CCH922507 from the Centers
for Disease Control and Prevention (CDC)